Highest-materiality recent filing
Annexon Q2 net loss $55.3M; BLA for tanruprubart on track for Q4 2026
Q2 net loss $55.3M ($0.28/share) vs $49.2M ($0.34) year ago; R&D $46.6M, G&A $10.6M.
Annexon appoints Mark Blumenkranz to board; Muneer Satter steps down after 11 years
Mark S. Blumenkranz appointed to Annexon board effective Aug 10, 2026, as Class II director with term to 2028 annual meeting.
Annexon reports all 10 GBS patients in FORWARD study improved within days on tanruprubart
All 10 patients showed rapid, clinically meaningful muscle strength improvement within 4 days of single 30 mg/kg infusion.
Annexon secures up to $200M credit facility from Oxford Finance; draws $50M initially
Up to $200M term loan facility with Oxford Finance; initial $50M drawn on July 30, 2026.
Elected Class III directors Bettina M. Cockroft, M.D. (101,594,745 for) and Douglas Love, Esq. (107,491,451 for).
Annexon Q1 net loss $44.1M ($0.23/sh); cash $225M; GA Ph3 data Q4 2026
Net loss $44.1M (-$0.23/sh) vs $54.4M (-$0.37/sh) Q1 2025; R&D $35.8M, G&A $10.3M.
Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.
Chairman Thomas G. Wiggans to retire from Annexon board at 2026 annual meeting
Mr. Wiggans notified the Board on Feb 12, 2026 of his intent to retire and not stand for reelection.
Annexon furnishes updated corporate presentation with no specific material changes disclosed
Company updated its corporate presentation for use at the 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026.
Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.
Annexon closes $86.25M public offering of common stock and pre-funded warrants
Priced 25,096,153 shares at $2.60/share and 3,750,000 pre-funded warrants at $2.599 each.
Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.
Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026
Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.
Annexon extends 2022 common warrants to June 2026, cash exercise only at $5.806875
Warrants exercisable for up to 6,877,622 shares of common stock.
Annexon stockholders elect Class II directors and ratify auditor at 2025 annual meeting
Class II directors Jung E. Choi and William D. Waddill elected with 83,207,282 and 62,741,842 votes for, respectively.
Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing
Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.
Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD
Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.
Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025
ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.
Annexon appoints commercial executive William 'BJ' Jones to board of directors
William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.
ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).
Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025
Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.
Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham
ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).
Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026
Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.
Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection
Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).
Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster
Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).
Elected William H. Carson, M.D. (78,919,065 for, 597,431 withheld) and Muneer A. Satter (60,965,423 for, 18,551,073 withheld) as Class I directors.
Annexon prices $125M public offering of common stock and pre-funded warrants
Priced 13,001,120 shares at $6.25/sh and 7M pre-funded warrants at $6.249/sh; gross proceeds $125M.
Phase 3 trial met primary endpoint: single infusion of ANX005 30 mg/kg achieved 2.4-fold improvement on GBS-DS at week 8 (p=0.0058).
Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024
Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.
Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024
ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.
Annexon reports Q4 2023 net loss $27.9M; cash $259.7M; Phase 3 GBS data Q2 2024
Net loss for FY2023 $134.2M vs $141.9M in prior year; R&D spend $113.8M.
Annexon holds virtual R&D Day focusing on Guillain-Barré Syndrome program
Presentation highlighted serious unmet need in Guillain-Barré Syndrome and Annexon's novel therapeutic approach.
Annexon outlines 2024 clinical milestones: Phase 3 GBS data H1 2024, GA trial start mid-2024
Phase 3 pivotal data for ANX005 in Guillain-Barré syndrome on track for first half of 2024; potential first approved treatment in U.S.
Annexon raises ~$125M via public offering of 25M shares and 18.4M pre-funded warrants at $2.88
Offering includes 25,035,000 common shares at $2.88/share and 18,379,861 pre-funded warrants at $2.879 each.
Annexon prices $125M underwritten offering of common stock and pre-funded warrants
Gross proceeds expected ~$125M from 25,035,000 shares at $2.880 and 18,379,861 pre-funded warrants at $2.879.
FDA agrees to prevention of ≥15-letter BCVA loss as primary endpoint; no requirement for surrogate structural endpoint.
Annexon Q3 net loss $32.5M, cash $165.3M; Phase 3 GBS enrollment complete, data H1 2024
Net loss of $32.5M ($0.43 per share) vs $35.1M ($1.42 per share) in Q3 2022.
EMA grants PRIME designation for Annexon's ANX007 in geographic atrophy
PRIME designation based on Phase 2 ARCHER trial showing preservation of visual function.
EMA grants orphan drug designation to ANX005 for GBS; Phase 3 enrollment complete
European Medicines Agency granted orphan drug designation to ANX005 for Guillain-Barré Syndrome.
Annexon Q2 net loss $35.2M; GA visual function data; GBS enrollment completion in H2 2023
ANX007 (GA) ARCHER Phase 2 data showed dose-dependent preservation of visual function; regulatory engagement planned.
Annexon appoints Jamie Dananberg as CMO; ARCHER trial shows ANX007 vision protection in GA
Jamie Dananberg, M.D., appointed chief medical officer; previously CMO at UNITY Biotechnology and exec at Takeda and Eli Lilly.
Annexon announces 2023 annual meeting voting results; all proposals approved
Class III directors Bettina Cockroft, Douglas Love, Thomas Wiggans re-elected with >32.4 M votes for each.
ANX007 monthly reduced risk of ≥15-letter BCVA loss by 72% (p=0.006); pooled 59% (p=0.008).
Annexon reports Q1 net loss $38.7M; pipeline milestones expected through 2024
Net loss $38.7M ($0.52/sh) vs $35.4M ($0.92/sh) in Q1 2022; R&D spend rose to $32.3M.
Annexon discloses $0.5M in SVB deposits; 0.2% of total cash
Silicon Valley Bank closed by FDIC on March 10, 2023.
Annexon reports Q4 2022 net loss of $34.4M; cash runway into 2025; reiterates pipeline milestones
Net loss of $34.4M for Q4 2022 ($141.9M full year) vs $37.4M Q4 2021.
Annexon prioritizes 4 flagship complement programs; GBS Phase 3 enrollment expanded to 220 patients
ANX005 Phase 3 in GBS expanded to 220 patients; pivotal data expected H1 2024.
Annexon appoints Dr. Rick Artis as Chief Scientific Officer, succeeding Dr. Larry Mattheakis
Dean 'Rick' Artis, Ph.D., appointed CSO effective January 6, 2023, succeeding Larry C. Mattheakis who is departing.
Annexon reports Q3 2022 net loss of $35.1M, cash $269.5M; pipeline updates in Jan 2023
Net loss of $35.1M ($0.51 per share) vs $35.6M ($0.93 per share) in Q3 2021.
Annexon Q2 net loss $37.1M; cash $177.6M, extended runway into H2 2025 via $130M private placement
Net loss of $37.1M ($0.96/share) vs. $31.3M ($0.82/share) in Q2 2021.
On January 9, 2025, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed William Jones, to the Board, effectively immediately.
Dr. Artis is succeeding Larry C. Mattheakis, Ph.D., who is departing from the Company and is no longer serving as Chief Scientific Officer effective as of January 6, 2023.
the appointment of Dean Richard Artis, Ph.D. as Chief Scientific Officer of the Company.
On February 1, 2022, Ricky Sun, Ph.D., notified the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) of his decision to resign from the Board, effective immediately.
On January 19, 2022, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., to the Board, effectively immediately.
appointed Ted Yednock, Ph.D. as Chief Innovation Officer
Larry Mattheakis, Ph.D. as Chief Scientific Officer
Max materiality 0.85 · Median 0.65 · Most common event other_material